The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...

Alcohol addiction devastates millions of lives each year, tearing apart families and leaving lasting scars. Yet, amid the struggle to curb its grip, a breakthrough may be on the horizon. Scientists ...

Altimmune plans Phase 2 trials in 2025 for pemvidutide in alcohol use disorder and liver disease, highlighting weight loss and liver health benefits.

Semaglutide shows promise in reducing alcohol cravings and consumption. Could it be a future treatment for AUD?

Screening should be conducted in patients exhibiting signs or symptoms of AUD. While there are multiple screening methods, the AUDIT-C (Alcohol Use Disorders Identification Test-Consumption ...

EUR/AUD slipped lower on Friday as uncertainty sparked by U.S. President Donald Trumps tariff war negatively impacted ...

A groundbreaking study from TrimBody MD has revealed that semaglutide, a GLP-1 agonist originally designed for diabetes and ...

Semaglutide may help reduce alcohol cravings and intake, according to a clinical trial. Participants receiving the drug drank ...

Image credit: Viktor Solomin/Stocksy. About 400 million people globally live with alcohol use disorder (AUD). AUD is linked to an increased risk for many diseases, including cancer. Although there ...

EUR/AUD eased slightly on Thursday as another round of tariff threats and uncertainty surrounding the proposed Ukraine ...

GLP-1 receptor agonists show promise in treating alcohol addiction by modulating reward pathways and reducing cravings, offering a novel therapeutic approach.

Evercore ISI likes the expansion of pemvidutide into alcohol liver disease and alcohol use disorder as it adds another leg to the pemvidutide ...